Subscribe
Sign in
Share this discussion
Tislelizumab, a novel anti-PD1 in hepatocellular carcinoma? Quality-of-Life, Non-Inferiority, and Duration of Treatment in RATIONALE-301.
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
Tislelizumab, a novel anti-PD1 in…
Timothée Olivier
Sep 8
17
Share this post
Tislelizumab, a novel anti-PD1 in hepatocellular carcinoma? Quality-of-Life, Non-Inferiority, and Duration of Treatment in RATIONALE-301.
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
Quality-of-life data should be interpreted with extra caution when censoring rates are high.
Read →
Comments
Share
Share
Copy link
Facebook
Email
Note
Other
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
Tislelizumab, a novel anti-PD1 in hepatocellular carcinoma? Quality-of-Life, Non-Inferiority, and Duration of Treatment in RATIONALE-301.
Tislelizumab, a novel anti-PD1 in…
Tislelizumab, a novel anti-PD1 in hepatocellular carcinoma? Quality-of-Life, Non-Inferiority, and Duration of Treatment in RATIONALE-301.
Quality-of-life data should be interpreted with extra caution when censoring rates are high.